Quarterly report pursuant to Section 13 or 15(d)

INTERIM FINANCIAL STATEMENTS (Details)

v3.5.0.2
INTERIM FINANCIAL STATEMENTS (Details) - USD ($)
Sep. 12, 2016
Sep. 30, 2016
Dec. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]      
Cash and liquid investments   $ 14,863,000  
Working capital   14,441,000  
Stockholders' equity   17,029,810 $ 16,070,636
Accumulated deficit   107,568,735 $ 105,582,439
Total value of capitalized patent costs that could be impaired due to inability to locate a new strategic target, a partner or other third-party interested in advancing development and commercial activities of the Venaxis appendicitis portfolio   $ 335,000  
BiOptix [Member]      
Business Acquisition [Line Items]      
Percentage of outstanding voting stock owned by parent 98.00%    
BiOptix [Member] | Common Stock [Member]      
Business Acquisition [Line Items]      
Equity consideration issued for acquisition, number of shares 627,010    
Value of equity consideration issued for acquisition $ 2,577,000